
Aehr Test Systems rose 143.2% from $24.59 to $59.81, ahead of the S&P 500's +10.5%. Its worst day was Nov 5 (−19.2%), and its low came Nov 20 at $19.40.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Aehr Test Systems closed at its lowest level of the year, 21.1% below where the year started.
−2.3% · S&P 500 −1.5%
EPS of $-0.04 beat the $-0.07 estimate on $9.9M revenue (est. $11.4M).
Story events cover the past 12 months · Times ET
+15.9% · S&P 500 +0.7%
The initial order includes multiple Aehr Sonoma ultra-high-power package-level test and burn-in systems for production burn-in of this next-generation device.
+26.2% · S&P 500 0.0%
Aehr Test Systems (NASDAQ:AEHR), a leading provider of test and burn-in solutions for semiconductor devices used in artificial intelligence (AI), data center, automotive, and industrial applications, today announced it
+23.1% · S&P 500 +2.9%
EPS of $-0.05 beat the $-0.10 estimate on $10.3M revenue (est. $11.7M).
+25.7% · S&P 500 +2.5%
Aehr Test Systems shares rose 20.7%, while the S&P 500 rose 0.1%.
+20.7% · S&P 500 +0.1%
EPS of $0.11 beat the $-0.02 estimate on $18.8M revenue (est. $18.7M); FY revenue guidance of $130.0M–$150.0M against the $85.4M consensus.
+21.9%, on 13M shares, the year's heaviest volume · S&P 500 +0.4%
Aehr Test Systems closed at its highest level of the year, 492.2% above where the year started.
+8.6% · S&P 500 −0.5%
EPS of $0.28 beat the $0.11 estimate on $33.0M revenue (est. $27.5M); FY revenue guidance of $150.0M against the $138.4M consensus.
+26.5% · S&P 500 +0.3%
Where it ended: a close of $59.81 on Nov 9, 2026. Up next: Q2 2027 earnings on Jan 7, 2027 (EPS est. $0.21, revenue est. $39.5M).
Nothing in the past 12 months.
All AEHR dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for AEHR and SPY from Benzinga historical bars. Not investment advice.